On CNBC’s “Options Action,” Carter Worth of Cornerstone Macro said SPDR S&P Biotech ETF (NYSE: XBI) has a bounce potential, having sold off to support.
XBI is an equal-weighted ETF and it is currently lagging iShares Biotechnology ETF (NASDAQ: IBB), which…

Click here to view the original article.